These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37972434)

  • 41. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system.
    Komatsu H; Tanaka T; Ye Z; Ikeda K; Matsuzaki T; Yasugi M; Hosoda M
    J Biomol Struct Dyn; 2023 Mar; 41(5):1767-1775. PubMed ID: 34984963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
    Thun-Hohenstein STD; Suits TF; Malla TR; Tumber A; Brewitz L; Choudhry H; Salah E; Schofield CJ
    ChemMedChem; 2022 Feb; 17(4):e202100582. PubMed ID: 34850566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
    Di Sarno V; Lauro G; Musella S; Ciaglia T; Vestuto V; Sala M; Scala MC; Smaldone G; Di Matteo F; Novi S; Tecce MF; Moltedo O; Bifulco G; Campiglia P; Gomez-Monterrey IM; Snoeck R; Andrei G; Ostacolo C; Bertamino A
    Eur J Med Chem; 2021 Dec; 226():113863. PubMed ID: 34571172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Fàbrega-Ferrer M; Herrera-Morandé A; Muriel-Goñi S; Pérez-Saavedra J; Bueno P; Castro V; Garaigorta U; Gastaminza P; Coll M
    Antiviral Res; 2022 Dec; 208():105458. PubMed ID: 36336176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease.
    Al-Wahaibi LH; Mostafa A; Mostafa YA; Abou-Ghadir OF; Abdelazeem AH; Gouda AM; Kutkat O; Abo Shama NM; Shehata M; Gomaa HAM; Abdelrahman MH; Mohamed FAM; Gu X; Ali MA; Trembleau L; Youssif BGM
    Bioorg Chem; 2021 Nov; 116():105363. PubMed ID: 34555629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 M
    Citarella A; Moi D; Pedrini M; Pérez-Peña H; Pieraccini S; Stagno C; Micale N; Schirmeister T; Sibille G; Gribaudo G; Silvani A; Passarella D; Giannini C
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diphenyl Diselenide and SARS-CoV-2:
    Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L
    J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
    Zhang K; Wang T; Li M; Liu M; Tang H; Wang L; Ye K; Yang J; Jiang S; Xiao Y; Xie Y; Lu M; Zhang X
    Eur J Med Chem; 2023 Sep; 257():115487. PubMed ID: 37257212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
    Geng ZZ; Atla S; Shaabani N; Vulupala V; Yang KS; Alugubelli YR; Khatua K; Chen PH; Xiao J; Blankenship LR; Ma XR; Vatansever EC; Cho CD; Ma Y; Allen R; Ji H; Xu S; Liu WR
    J Med Chem; 2023 Aug; 66(16):11040-11055. PubMed ID: 37561993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
    Deodato D; Asad N; Dore TM
    Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
    Freire MCLC; Noske GD; Bitencourt NV; Sanches PRS; Santos-Filho NA; Gawriljuk VO; de Souza EP; Nogueira VHR; de Godoy MO; Nakamura AM; Fernandes RS; Godoy AS; Juliano MA; Peres BM; Barbosa CG; Moraes CB; Freitas-Junior LHG; Cilli EM; Guido RVC; Oliva G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
    Sies H; Parnham MJ
    Free Radic Biol Med; 2020 Aug; 156():107-112. PubMed ID: 32598985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
    Menéndez CA; Byléhn F; Perez-Lemus GR; Alvarado W; de Pablo JJ
    Sci Adv; 2020 Sep; 6(37):. PubMed ID: 32917717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
    Pillaiyar T; Flury P; Krüger N; Su H; Schäkel L; Barbosa Da Silva E; Eppler O; Kronenberger T; Nie T; Luedtke S; Rocha C; Sylvester K; Petry MRI; McKerrow JH; Poso A; Pöhlmann S; Gütschow M; O'Donoghue AJ; Xu Y; Müller CE; Laufer SA
    J Med Chem; 2022 Jul; 65(13):9376-9395. PubMed ID: 35709506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amentoflavone derivatives significantly act towards the main protease (3CL
    Dey D; Hossain R; Biswas P; Paul P; Islam MA; Ema TI; Gain BK; Hasan MM; Bibi S; Islam MT; Rahman MA; Kim B
    Mol Divers; 2023 Apr; 27(2):857-871. PubMed ID: 35639226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
    Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.